EGFR and non-small cell lung carcinoma: A Taiwanese retrospective cohort study15 involving 448 patients with advanced NSCLC and EGFR-activating mutations who received EGFR-TKIs as first-line therapy showed that afatinib and erlotinib exerted significant benefits in PFS compared to gefitinib.